1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
Remicade (Infliximab) Biosimilar Clinical Trial Insight

Remicade (Infliximab) Biosimilar Clinical Trial Insight

  • October 2016
  • 50 pages
  • ID: 4397342
  • Format: PDF
  • By PNS Pharma

Summary

Table of Contents

“Remicade (Infliximab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 17 biosimilar version of Remicade drug in clinical pipeline. Currently there are 2 biosimilars in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 3 biosimilar version of Remicade are commercially available in India, Brazil and European countries for the treatment of Ankylosing spondylitis, Crohn's disease and Rheumatoid Arthritis. The patent on Remicade is set to expire in 2018 for US and 2017 for rest of world.


Remicade is the trade name for infliximab which is a chimeric monoclonal antibody biologic drug, marketed by Janssen Biotech. Infliximab is used to fight against tumor necrosis factor alpha (TNF-?) to treat auto immune diseases such as rheumatoid arthritis. The drug is a purified form of recombinant DNA-derived human-mouse monoclonal antibodies consisting of mouse and human’s heavy and light chain variable regions. It is a prescribed drug, approved by Food and Drug Association for the treatment of Crohn’s disease, Pediatric Crohn’s disease, Ulcerative colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing spondylitis and Plaque psoriatic.


FDA approved infliximab in September 2006, for chronic Plaque Psoriasis. Infliximab comes under the form of naturally occurring antibodies (anti-TNF bodies) with the ability to neutralize all forms of TNF.It is capable of breaking down of cell causing inflammatory process. Biological activities such as pro inflammatory cytokines, enhancement of leukocyte movement and increasing the release of adhesion molecules are attributed to TNF-?.
Infliximab is made up of human and mouse antibodies. It is an artificial antibody originally developed from mice. Due to human immune reaction to mouse proteins, the mouse common domains are replaced with human antibody domains. Infliximab is has main key components as human mouse antibody amino acids because of which is referred aschimeric monoclonal antibody.


Infliximab works by binding action of remicade with TNF-?. Playing a crucial role in auto immune systems, TNF-? is a chemical messenger. In the case of rheumatoid arthritis, infliximab works to prevent TNF-? by attaching to its receptor in the cell. Infliximab works by neutralizing the biological activity of TNF-?. It inhibits the functional activity of wide variety utilizing human fibroblasts, endothelial cells, neutrophils, B and T-lymphocytes and epithelial cells. Though, the biological responses through which remicade exert clinical effects in the body are still considered to be unknown.


Remicade is necessarily induced intravenously because of the fact that the drug can be destroyed by the digestive system of a patient in case given by mouth. The dosages are typically administered by infusion within the interval of 6 to 8 weeks. The initial process involves the 3 starter infusions over first 6 weeks, followed by 2 more after next 2 and 4 weeks. Along with remicade, patients are prescribed with a particular amount of medication, depending upon the patient’s weight to reduce its side effects
Similar to other TNF inhibitors, infliximab is an expensive drug costing range fromUS$ 1300 – US$ 2500 for every dosage. It is manufactured as a sterile lyophilized white freeze dried powder which necessarily requires administration and reconstitution by a health care professional. Due to this need of extra care during treatment and infusion of remicade, it is a part of major health insurances.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Chromatography Resin Market by Type, Technique, Application, Region - Global Forecast to 2024

Chromatography Resin Market by Type, Technique, Application, Region - Global Forecast to 2024

  • $ 4950
  • December 2019

Growing demand for therapeutic antibodies and increasing biopharmaceutical R&D activities are expected to drive the chromatography resin market.The global chromatography resin market size is projected ...

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2019

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H2 2019, provides ...

Nasal Polyps - Pipeline Review, H2 2019

Nasal Polyps - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Nasal Polyps - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Nasal Polyps - Pipeline Review, H2 2019, provides an overview of the Nasal Polyps (Ear Nose ...


ref:plp2016

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on